Mae. C. Jemison receives the supreme recoginition for an individual’s efforts to improve the human condition


Click to view

Stanley T. Crooke, MD, Ph.D., Founder, Chief Executive Officer and Chairman of the Board, n-Lorem foundation


l-r: Cato T.  Laurencin, Mae C. Jemison, Michael Rosenblatt

In offering this recognition, our committee of distinguished scientists and Nobel laureates cites your exceptional Scientific Achievements. As a physician, engineer, and former NASA astronaut, you have demonstrated excellence in the fields of medicine and space science. For instance, your groundbreaking research aboard the Space Shuttle Endeavour in 1992 advanced our understanding of human physiology and the effects of space travel on the human body, leaving a lasting impact on space exploration.

Moreover, beyond your space career, our committee acknowledges your tireless Medical Advocacy efforts. Your commitment to promoting diversity in STEM fields and inspiring young students, particularly from underrepresented communities, has been truly commendable. Your mentorship and advocacy for science education and healthcare access make you a notable figure in the medical community, empowering future generations to pursue careers in science and medicine.

Furthermore, our committee appreciates your exceptional Humanitarian Efforts. Your involvement in humanitarian initiatives, such as serving as a Peace Corps medical officer in West Africa and working on projects to improve healthcare infrastructure and medical training in underserved areas, showcases your dedication to addressing global health issues through science and medicine.

In conclusion, your outstanding contributions to science, medicine, and humanitarian efforts have left an indelible mark on society, making you a true inspiration to us all.

A trailblazer in so many ways
Dr. Mae C. Jemison, best known for her pioneering journey as the first African American woman to travel in space, is once again in the spotlight. This time, it’s for her unwavering commitment to global health, science education, and interdisciplinary collaborations.
After her illustrious career at NASA, where she flew aboard the Space Shuttle Endeavour, Jemison directed her energies towards the healthcare sector, especially focusing on developing countries. She took the helm of the Jemison Group, a cutting-edge organization dedicated to researching, developing, and marketing advanced technologies, primarily in the realm of healthcare. But Jemison’s passion isn’t just confined to health. She’s also a staunch advocate for inclusive science education. Her “Dorothy Jemison Foundation for Excellence” underscores the significance of science literacy for all, ensuring that the wonders of the scientific world are accessible to everyone.

Taking an interdisciplinary approach, Jemison has highlighted the synergy between arts and sciences. Her international science camp, “The Earth We Share,” caters to students between 12-16 years. Through this initiative, students are encouraged to engage in critical thinking and problem-solving in real-world situations, a trait that’s invaluable in today’s ever-evolving landscape. Jemison’s post-NASA endeavors also emphasize the importance of international collaboration. Aligned with the global vision of the Prix Galien award, she pushes for global advancements and partnerships in the healthcare sector. Given her vast contributions across multiple fields and her enduring commitment to diversity, inclusion, and global health improvement, calls are growing louder for Jemison to be recognized with The Roy Vagelos Pro Bono Humanum Award for Global Health Equity. It would be a fitting tribute to a figure who has not only broken barriers in space exploration but continues to champion causes for the betterment of humanity.


The Galien Foundation’s Prix Galien, Roy Vagelos, Pro Bono Humanum Award is in honor of Dr. P. Roy Vagelos, Retired Chairman and CEO, Merck & Co., Inc. Chairman of the Board, Regeneron Pharmaceuticals. Dr. Vagelos, who chaired the Prix Galien USA Awards Committee from its inception until December 2017, was also the first recipient of the Pro Bono Humanum Award, established in 2007 under the sponsorship of the late Foundation Honorary President and 1986 Nobel Peace Prize recipient, Pr. Elie Wiesel.

The annual Prix Galien, Roy Vagelos, Pro Bono Humanum Award recognizes an individual’s outstanding efforts to improving the human condition through the application of pharmaceutical science to problems of developing or underserved populations worldwide.

Image 49-1

P. Roy Vagelos
Prix Galien USA Committee Chair 2012-2017

Past Pro Bono Humanum Award Winners:

Stanley T. Crooke

In recognition of his nearly 50 years of dedication to a novel, clinically endorsed concept of using synthetic oligonucleotides to control the expression of genes and proteins that impact disease. His singular dedication to this RNA-driven antisense platform provided a new, highly personalized pathway to resolving some of the most difficult biomedical challenges, with the ultimate potential of treating multiple infections, inflammatory conditions and cancers targeted to individual patient profiles and with minimal side-effects. Due to Dr. Crooke’s years of effort as a researcher, corporate R&D executive, biotech innovator and philanthropist, nearly a dozen antisense oligonucleotides (ASO) have been approved for clinical use since 1998; additional clinical trials focused in high unmet medical need areas like neuroscience are underway. Dr. Crooke is also recognized for his leadership in being among the first in industry to make a commitment to open science a key element of the modern R&D enterprise and to embrace the principle that even patients with the rarest of afflictions deserve the best talent and expertise our R&D industry can offer. Untold thousands of patients formerly with no hope of a cure stand to benefit from his belief in the promise of this entirely new class of medicines.

(l-r) Stephane Bancel; Albert Bourla; Alex Gorsky; David Ricks; Pascal Soriot; George D. Yancopoulos

In recognition of the monumental feat of having developed, in less than a year, vaccines against COVID-19, as well as having developed several novel antiviral drugs that treat COVID-19 symptoms based on innovative monoclonal antibody platforms. The six companies together responded to the pandemic in record time, with safe, effective treatments that hold the promise of reducing mortality and restoring normal life for untold millions of vulnerable patients.

Dr. William H. Foege

In recognition of this role in building the global strategy that resulted in the eradication of this smallpox virus in 1980, a success that helped foster higher rates of immunization against many other infectious and communicable diseases throughout the developing world.

Jim and Marilyn Simons

The Simons Foundation In recognition of their proactive support of basic scientific research undertaken in the pursuit of understanding the phenomena of our world, often including research by scientists in the early stages of their careers, a new collaborative funding model to facilitate cross-disciplinary breakthroughs, and efforts to inspire emerging and current philanthropists to dedicate a portion of their philanthropy to basic science.

Bill and Melinda Gates

Bill & Melinda Gates Foundation

In recognition of their extraordinary work championing scientific and technological innovation to improve life for the world’s poorest people. As co-chairs of the Bill & Melinda Gates Foundation, they have catalyzed unprecedented progress in global health, poverty reduction, and public education in the U.S.

Jimmy Carter

Former U.S. President &
Co-Founder, The Carter Center

For playing a leadership role in the elimination of river blindness in four of the six Latin American countries where it was endemic and halting the disease’s transmission in several locations in Africa where more than 99 percent of the global cases exist.

Paula S. Apsell

Executive Producer, PBS NOVA series & Director, Science Unit, WGBH

For turning great science into a human story, showing that scientific literacy is society’s first line of defense against the destructive forces of fear and ignorance that challenge further progress in human health.

Pr. Mary-Claire King

Professor, Genome Sciences and Medical Genetics, University of Washington

In recognition of her work in transforming the application of human genetics to medicine through identification of the first gene, BRCA1, responsible for inherited susceptibility to breast cancer. And for pioneering the application of genetic sequencing in forensics to identify victims of human rights abuse.

Dr. Bernard Kouchner

Co-Founder, Doctors Without Border & Former French Minister of Foreign and European Affairs

In recognition of his role in the creation, from amongst French doctors, this group of “Doctors Without Borders” who have lent the modern field of humanitarian medicine both legitimacy and worldwide acclaim and for his fieldwork that has nurtured and developed, not only among public opinion but also within various governments, the notion of the universality of humanitarian action and the concept of the Non-Governmental Organization.

Dr. Anthony Fauci

Director, U.S. National Institute of Allergy and Infectious Diseases

For his paramount contributions to basic and clinical research on the pathogenesis and treatment of immune mediated and infectious diseases.

Dr. Francis S. Collins

Director, U.S. National Institutes of Health

Dr. Collins, Director of the National Institutes of Health (N.I.H). In recognition of his contribution to the ethical implications of scientific research.

Pr. Paul Farmer

Chief Strategist and Co-Founder, Partners In Health

For his humanitarian work in Haiti and throughout the world, including advancing the fight against infectious diseases, including AIDS and tuberculosis.

Bill Clinton and Philippe Douste-Blazy

Founder, Clinton Foundation and Former U.S. President; Chairman, UNITAID In recognition of their achievements in providing treatment and increasing access to medicines for underserved populations through the UNITAID and Clinton Foundation HIV/AIDS Initiative (CHAI) partnership.

Barry Bloom and Jeffrey Sachs

Professor of Public Health, Harvard University; Director, Earth Institute, Columbia University Harvard Professor Barry Bloom for bringing the fruits of basic biological science to those who are most needy. Columbia University Earth Institute Director Jeffrey Sachs for bringing the fruits of scholarly economics to bear our problems that have plagued the world for millennia.

Sheldon Segal and the Population Council

Former Chairman, Population Council

For their global efforts in support of reproductive health and family planning.

P. Roy Vagelos

Retired Chairman and CEO, Merck & Co., Inc.; Chairman of the Board Regeneron Pharmaceuticals, Inc.

For the River Blindness Program and his historic decision to donate the drug Mectizan to more than 530 million people in 34 countries to treat and prevent river blindness “as much as necessary for as long as necessary.”